

# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

## PRIMARY IR CONTACT

Investor Relations  
**Phone:** 647-479-9825  
**E-mail:** ir@aptose.com

## STOCK PERFORMANCE

### APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	<b>Can\$1.58</b>
Change (%)	▲ 0.13 (8.97%)
Volume	72,724
52 Week Low	Can\$1.05
Market Cap	Can\$33,036,465
Rolling EPS	-1.31
PE Ratio	0
Shares Outstanding	22,783,769
Data as of June 28, 2017 3:59 p.m. ET	



### APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$1.22</b>
Change (%)	▲ 0.12 (10.91%)
Volume	1,103,899
52 Week Low	\$0.78
Market Cap	\$25,062,146
Rolling EPS	-0.98
PE Ratio	0
Shares Outstanding	22,783,769
Data as of June 28, 2017 4:00 p.m. ET	



## RECENT PRESS RELEASES & UPCOMING EVENTS

June 6, 2017  
Aptose Biosciences Announces Results of Annual Meeting  
of Shareholders  
May 11, 2017  
Aptose Reports Results for the First Quarter Ended March  
31, 2017  
May 8, 2017  
Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor  
CG'806 Presented at AACR Hematologic Malignancies  
Meeting

There are currently no events scheduled.

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
June 9, 2017	SC 13G
June 7, 2017	6-K
June 6, 2017	6-K
May 12, 2017	6-K

## CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Avanish Vellanki	Senior Vice President, Chief Business Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Elizabeth Williams	Vice President, Finance and Administration
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.